InvestSMART

Resonance Health Limited (ASX:RHT)

ALERT: Price-sensitive ASX Announcement for RHT
Current share price for RHT : $0.077 0.012 (18.46%)+
Announcement
Release
28 Aug 2026 9:28AM
Price at Release
$0.065
Full Release
download
Summary
Resonance Health Limited announced its FY26 full-year results for the year ended 30 June 2026, reporting record revenue of $15.8 million, up 42% on FY25, and a return to profitability with net profit after tax of $1.5 million, positive basic EPS of 0.32 cents, and Normalised EBITDA of $2.6 million at a 16% operating margin, in line with upgraded guidance; performance was driven by strong growth across Resonance Clinical, TrialsWest and the Software-as-a-Medical Device business, with operating cashflow positive in every quarter, net cash from operating activities of $2.9 million, free cashflow of $2.8 million and year-end cash of $4.8 million, while operationally the company highlighted progress on its $13.8 million major-pharma clinical trial, a SaMD forward order and tender pipeline above $12 million, profitable and expanding TrialsWest clinics, continued development of its non-invasive liver fibrosis project, and FY27 guidance for revenue of $17 million to $22 million and Normalised EBITDA of $2.6 million to $3.6 million, with a live FY26 full-year results investor webinar scheduled for 28 August 2026.
Key Points
  • FY26 revenue increased 42% to $15.8 million from $11.1 million in FY25.
  • The company returned to full-year profitability with net profit after tax of $1.5 million, compared with a $1.7 million loss in FY25.
  • Basic earnings per share were positive at 0.32 cents, versus a 0.38 cent loss in FY25.
  • Normalised EBITDA rose 83% to $2.6 million, representing a 16% operating margin.
  • Resonance Health achieved its upgraded FY26 guidance of about $16 million revenue and $2.6 million EBITDA.
  • Cash receipts from customers were $14.3 million and operating cashflow was positive in all four quarters.
  • Net cash from operating activities was $2.9 million and free cashflow was $2.8 million, up 148% on FY25.
  • Employee costs fell from 51% to 41% of revenue, reflecting early benefits from automation and scale.
  • Year-end cash at bank was $4.8 million and net cash was $2.3 million after $2.5 million of bank debt drawn.
  • Resonance Clinical revenue increased 81% to $7.5 million, making it the group’s largest segment by revenue.
  • The $13.8 million major-pharma clinical trial hit its 60-patient recruitment target in April 2026, with invoicing continuing into FY27.
  • Total major-pharma clinical trial contract wins since August 2023 reached $20.1 million.
  • TrialsWest performed ahead of expectations, with Osborne Park consistently profitable and Mandurah approaching breakeven in its first year.
  • The SaMD business expanded clinical trial volumes and its forward order and tendered pipeline exceeded $12 million.
  • The company completed testing and validation of its new Bridge automation technology, with pilot deployments continuing into FY27.
  • The extended proof-of-concept trial for the non-invasive MRI Liver Fibrosis project was fully enrolled, with data analysis underway.
  • ASX confirmed on 12 August 2026 that the company no longer needs to lodge Appendix 4C quarterly cashflow reports.
  • FY27 guidance is for revenue of $17 million to $22 million and Normalised EBITDA of $2.6 million to $3.6 million.
  • A live FY26 Full Year Results & Investor Webinar was scheduled for 10.00 a.m. AWST on Friday, 28 August 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.